Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
RLAY compared with AMLX: revenue, margins and what each company keeps, and the suppliers and customers both name
RLAY
Relay Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
AMLX
Amylyx Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
RLAY
Relay Therapeutics, Inc.
vs
AMLX
Amylyx Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
RLAY: latest quarter is a loss; flow not drawable. AMLX: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only RLAY
3
—
D.E. Shaw Research
unlisted
supplier
—
Elevar Therapeutics
unlisted
customer
—
Genentech
unlisted
customer
Shared
0
No disclosed counterparties: AMLX.
Only AMLX
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
RLAY, solid
AMLX, dashed
RLAY
Relay Therapeutics, Inc.
Change
18.35
▼
−5.78%
· post 18.35
Mkt cap
$4.0B
Revenue
$350,000
Q2 FY26
AMLX
Amylyx Pharmaceuticals, Inc.
Change
28.86
▲
+0.63%
· post 29.02
Closed
Oct 30 '26
Mkt cap
$3.2B
Revenue
$416,000
Q3 FY24
vs
Compare
Closed
Oct 30 '26
RLAY
Relay Therapeutics, Inc.
vs
AMLX
Amylyx Pharmaceuticals, Inc.
18.35
▼
−5.78%
post 18.35
Price
28.86
▲
+0.63%
post 29.02
$4.0B
Mkt cap
$3.2B
Q2 FY26
$350,000
Revenue
$416,000
Q3 FY24
Change
Change
RLAY
18.35
▼
−5.78%
vs
AMLX
28.86
▲
+0.63%
Closed
Oct 30 '26